DEFEND CF: Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosis
Sensitive and reliable tests are required to monitor lung disease severity in cystic fibrosis.
AREST CF Early Surveillance Program
The Early Surveillance Program (ESP) is the platform upon which the AREST CF research program is based.
COMBAT CF: A phase 3 multi-centre randomized placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis.
A phase 3 multi-centre randomized placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis